A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Inclusion Criteria: * Foveal center-involved macular edema due to branch retinal vein occlusion (BRVO), diagnosed no longer than 4 months prior to the screening visit * Best-corrected visual acuity (BCVA) of 73 to 19 letters, inclusive (20/40 to 20/400 approximate Snellen equivalent) on Day 1 * Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis * For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs during the treatment period and for 3 months after the final dose of study treatment Exclusion Criteria: * Any major illness or major surgical procedure within 1 month before screening * Uncontrolled blood pressure * Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1 * Pregnant or breastfeeding, or intending to become pregnant during the study Ocular Exclusion Criteria for Study Eye: * History of previous episodes of macular edema due to RVO or persistent macular edema due to RVO diagnosed more than 4 months before screening * Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than macular edema due to RVO in the study eye (e.g., ischemic maculopathy, Irvine-Gass syndrome, foveal atrophy, foveal fibrosis, pigment abnormalities, dense subfoveal hard…